JP2018502120A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502120A5
JP2018502120A5 JP2017535690A JP2017535690A JP2018502120A5 JP 2018502120 A5 JP2018502120 A5 JP 2018502120A5 JP 2017535690 A JP2017535690 A JP 2017535690A JP 2017535690 A JP2017535690 A JP 2017535690A JP 2018502120 A5 JP2018502120 A5 JP 2018502120A5
Authority
JP
Japan
Prior art keywords
combination according
cpi
antigen
binding fragment
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017535690A
Other languages
English (en)
Japanese (ja)
Other versions
JP6885867B2 (ja
JP2018502120A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/067269 external-priority patent/WO2016109310A1/en
Publication of JP2018502120A publication Critical patent/JP2018502120A/ja
Publication of JP2018502120A5 publication Critical patent/JP2018502120A5/ja
Application granted granted Critical
Publication of JP6885867B2 publication Critical patent/JP6885867B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017535690A 2014-12-31 2015-12-22 組合せ腫瘍免疫療法 Active JP6885867B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462098568P 2014-12-31 2014-12-31
US62/098,568 2014-12-31
US201562106526P 2015-01-22 2015-01-22
US62/106,526 2015-01-22
US201562118165P 2015-02-19 2015-02-19
US62/118,165 2015-02-19
PCT/US2015/067269 WO2016109310A1 (en) 2014-12-31 2015-12-22 Combination tumor immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020187016A Division JP2021014465A (ja) 2014-12-31 2020-11-10 組合せ腫瘍免疫療法

Publications (3)

Publication Number Publication Date
JP2018502120A JP2018502120A (ja) 2018-01-25
JP2018502120A5 true JP2018502120A5 (enExample) 2019-02-14
JP6885867B2 JP6885867B2 (ja) 2021-06-16

Family

ID=56284932

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017535690A Active JP6885867B2 (ja) 2014-12-31 2015-12-22 組合せ腫瘍免疫療法
JP2020187016A Withdrawn JP2021014465A (ja) 2014-12-31 2020-11-10 組合せ腫瘍免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020187016A Withdrawn JP2021014465A (ja) 2014-12-31 2020-11-10 組合せ腫瘍免疫療法

Country Status (20)

Country Link
US (3) US10682365B2 (enExample)
EP (2) EP3240801B1 (enExample)
JP (2) JP6885867B2 (enExample)
CN (2) CN107428813B (enExample)
AU (2) AU2015374385B2 (enExample)
CY (1) CY1123868T1 (enExample)
DK (1) DK3240801T3 (enExample)
ES (1) ES2856844T3 (enExample)
HR (1) HRP20210200T1 (enExample)
HU (1) HUE053145T2 (enExample)
LT (1) LT3240801T (enExample)
MX (2) MX393750B (enExample)
NZ (2) NZ734144A (enExample)
PL (1) PL3240801T3 (enExample)
PT (1) PT3240801T (enExample)
RS (1) RS61470B1 (enExample)
SI (1) SI3240801T1 (enExample)
SM (1) SMT202100094T1 (enExample)
WO (1) WO2016109310A1 (enExample)
ZA (1) ZA202005298B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200030375A1 (en) * 2012-06-27 2020-01-30 Kenichiro Hasumi Therapy and methods of introducing immature dendritic cells and/or cytoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
LT3240801T (lt) * 2014-12-31 2021-02-25 Checkmate Pharmaceuticals, Inc. Kombinuota navikų imunoterapija
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
BR112017025562A2 (pt) * 2015-05-29 2018-08-07 Merck Sharp & Dohme Corp. métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
EP3682889B1 (en) * 2015-08-06 2023-02-01 Regents of the University of Minnesota Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
EP3213768A1 (en) 2016-03-01 2017-09-06 LODOCO CLINICAL Kft Combination of low dose immune checkpoint blockade with high dose il-2 for treating metastatic cancer
WO2017173334A1 (en) * 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
EP3666794A1 (en) 2016-11-01 2020-06-17 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
WO2018115051A1 (en) 2016-12-22 2018-06-28 F. Hoffmann-La Roche Ag Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
BR112019014187A2 (pt) 2017-01-09 2020-02-11 Tesaro, Inc. Métodos de tratamento de câncer com anticorpos anti-pd-1
WO2018181542A1 (ja) * 2017-03-29 2018-10-04 テルモ株式会社 アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
US12246031B2 (en) * 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
MX2020010410A (es) 2018-04-09 2021-01-15 Checkmate Pharmaceuticals Empaquetado de oligonucleotidos en particulas similares a virus.
WO2019200238A1 (en) 2018-04-14 2019-10-17 Dynavax Technologies Corporation Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer
CN108486120B (zh) * 2018-04-28 2019-12-06 新乡医学院 一种新型CpG ODN序列及其在抗黑色素瘤上的应用
EP3566718A1 (en) * 2018-05-07 2019-11-13 Universitätsmedizin der Johannes Gutenberg-Universität Mainz A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer
EP3802613A4 (en) * 2018-06-05 2022-03-09 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. DIMER AND ITS USE
WO2020081398A1 (en) * 2018-10-14 2020-04-23 Dynavax Technologies Corporation Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
US20210340544A1 (en) * 2018-10-18 2021-11-04 Idera Pharmaceuticals, Inc. Tlr9 modulators for treating cancer
WO2020123388A1 (en) 2018-12-11 2020-06-18 Board Of Regents, The University Of Texas System Radiotherapies and uses thereof
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
EP3845649B1 (en) * 2019-12-31 2025-09-24 Industrial Technology Research Institute Nucleic acid-drug complex and use thereof
CN115279793B (zh) * 2020-05-14 2025-12-23 安立玺荣生医(香港)有限公司 抗pd-l1抗体和抗pd-l1/il10融合蛋白
WO2022110010A1 (zh) * 2020-11-27 2022-06-02 苏州吉玛基因股份有限公司 免疫激活剂、抗原和抗体在制备预防、治疗肿瘤产品中的应用
CN114099535B (zh) * 2020-12-10 2023-01-03 南京吉迈生物技术有限公司 Toll样受体9(TLR9)激动剂水凝胶免疫调节组合物
KR20240004419A (ko) * 2021-04-01 2024-01-11 트라이살루스 라이프 사이언시즈, 인크. 톨-유사 수용체 작용제를 사용한 암 요법
US11898147B2 (en) * 2021-09-06 2024-02-13 National Health Research Institutes CpG-oligodeoxynucleotide compounds in combination with immune modulators for cancer immunotherapy
US20250009918A1 (en) * 2021-11-24 2025-01-09 Wisconsin Alumni Research Foundation Nanoparticles for potentiating effects of radiation therapy on anti-cancer immunotherapy
IL314037A (en) 2022-01-03 2024-09-01 Checkmate Pharmaceuticals Inc Transcriptional biomarkers for response to innate immune activators
US20240180952A1 (en) * 2022-01-11 2024-06-06 Trisalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists
CN114982711B (zh) * 2022-05-30 2023-11-10 广东省人民医院 小鼠胃间质瘤自发成瘤模型及其构建方法和应用
WO2025117535A1 (en) * 2023-11-29 2025-06-05 Zola Therapeutics Inc. Synthetic immunostimulatory nucleic acids for immunotherapy of cancer and other diseases

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
ATE75483T1 (de) 1981-10-23 1992-05-15 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100238712B1 (ko) 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US5859231A (en) 1993-09-03 1999-01-12 Duke University Synthesis of oligonucleotides with boranophosphonate linkages
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US20020088014A1 (en) 1996-05-31 2002-07-04 Xiangming Fang Minimal adenovirus mediated recombinant vaccine
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
DE19826758C1 (de) 1998-06-15 1999-10-21 Soft Gene Gmbh Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte
WO2000006588A1 (en) 1998-07-27 2000-02-10 University Of Iowa Research Foundation STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
PT1813624E (pt) 1998-10-23 2010-10-27 Amgen Inc Métodos e composições para a prevenção e tratamento da anemia
JP5341287B2 (ja) 1998-12-03 2013-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｃｔｌａ−４遮断薬を用いる自己抗原に対するｔ細胞の刺激
DK2112166T3 (en) 1998-12-23 2019-02-04 Pfizer Human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
EP2292651A1 (en) 2000-04-21 2011-03-09 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
CN1604795B (zh) 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
DE60234375D1 (de) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
EP2305312B1 (en) 2001-10-10 2015-03-04 ratiopharm GmbH Remodelling and glycoconjugation of follicle-stimulating hormone (FSH)
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
JP5022028B2 (ja) 2003-03-26 2012-09-12 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト メラン−ａペプチドアナログ−ウイルス様粒子コンジュゲート
DK1699480T3 (da) 2003-12-30 2011-10-10 Mologen Ag Allogent terapeutisk tumormiddel
CN1918293A (zh) 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US20090117132A1 (en) 2005-07-07 2009-05-07 Pfizer, Inc. Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment
WO2007059041A2 (en) * 2005-11-11 2007-05-24 Pfizer, Inc. Combinations and methods of using an immunomodulatory oligodeoxynucleotide
US20070184068A1 (en) 2005-12-14 2007-08-09 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
DK1991678T4 (da) 2006-02-15 2020-10-19 Rechtsanwalt Thomas Beck Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer
CN101479375B (zh) 2006-05-03 2016-03-30 科罗拉多州立大学董事会 Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其作为增强细胞免疫的治疗剂的用途
CN101466720B (zh) 2006-06-12 2013-01-02 赛托斯生物技术公司 向rna噬菌体的病毒样颗粒内包装寡核苷酸的方法
KR101251707B1 (ko) 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
JP5389662B2 (ja) 2006-12-12 2014-01-15 サイトス バイオテクノロジー アーゲー 高濃度のグアニン・モノマーを含有するオリゴヌクレオチド
WO2009022215A1 (en) 2007-08-13 2009-02-19 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
WO2012006634A2 (en) * 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
CA2871711A1 (en) * 2012-05-04 2013-11-07 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users
LT3240801T (lt) * 2014-12-31 2021-02-25 Checkmate Pharmaceuticals, Inc. Kombinuota navikų imunoterapija
BR112017025562A2 (pt) * 2015-05-29 2018-08-07 Merck Sharp & Dohme Corp. métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer
US9917100B2 (en) 2015-11-20 2018-03-13 Sandisk Technologies Llc Three-dimensional NAND device containing support pedestal structures for a buried source line and method of making the same
ITUA20162720A1 (it) 2016-04-19 2017-10-19 Risco Spa Apparecchiatura per preparare un prodotto alimentare

Similar Documents

Publication Publication Date Title
JP2018502120A5 (enExample)
HRP20210200T1 (hr) Kombinirana antitumorska imunoterapija
Abbott et al. Cancer and the immune system: the history and background of immunotherapy
Hu et al. The abscopal effect of radiation therapy: what is it and how can we use it in breast cancer?
JP2016536286A5 (enExample)
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
Borg et al. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study
JP2017516775A5 (enExample)
JP2015532292A5 (enExample)
JP2015534577A5 (enExample)
JP2019532047A5 (enExample)
RU2017117664A (ru) Комбинация
RU2018135317A (ru) Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
JP2017533912A5 (enExample)
MX2021008224A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
MX2023002554A (es) Anticuerpos anti-il-1r3 humanizados.
JP2019504105A5 (enExample)
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
JP2016502515A5 (enExample)
JP2017538680A5 (enExample)
Feng et al. Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
MX2021010228A (es) Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel.
Fleischmann et al. Radioimmunotherapy: future prospects from the perspective of brachytherapy
JP2018509423A5 (enExample)